Jefferies Financial Group
NTLA icon

Jefferies Financial Group’s Intellia Therapeutics NTLA Stock Holding History

Jefferies Financial Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-3,000
Closed -$50.8K – 1661
2026
Q2 		$50.8K Buy
3,000
+2,000
+200% +$28K ﹤0.01% 1574
2026
Q1 		$12.8K Buy
+1,000
New +$12.7K ﹤0.01% 1683
2024
Q3 		– Sell
-700
Closed -$15.7K – 1662
2024
Q2 		$15.7K Buy
+700
New +$16.7K ﹤0.01% 1351

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Contrarius Group Holdings
Contrarius Group Holdings Hamilton, Bermuda $2.05B AUM 66.09% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Jefferies Financial Group's NTLA Position: Q3 2026 in Review

Jefferies Financial Group sold out of Intellia Therapeutics (NTLA) in Q3 2026, closing a stake of 3,000 shares — an estimated $50.8K sold.

Jefferies Financial Group first reported a position in NTLA in Q2 2024 and held it in 3 quarters. The position peaked at $50.8K in Q2 2026. 156 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Jefferies Financial Group reported no remaining Intellia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 3,000 Intellia Therapeutics shares in Q3 2026, an estimated $50.8K.
  • Jefferies Financial Group first reported a position in Intellia Therapeutics in Q2 2024 and held it in 3 quarters.
  • Jefferies Financial Group's Intellia Therapeutics position peaked at $50.8K in Q2 2026.
  • 156 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.